ATE519763T1 - Pyrrolopyrazin-kinasehemmer - Google Patents

Pyrrolopyrazin-kinasehemmer

Info

Publication number: ATE519763T1
Authority: AT; Austria
Prior art keywords: kinase inhibitors; pyrrolopyrazine; pyrrolopyrazine kinase; inhibitors; kinase
Prior art date: 2008-02-25

Application number

AT09714560T

Other languages

English (en)

Inventor

Bois Daisy Du

Todd Elworthy

Robert HENDRICKS

Johannes Hermann

Rama KONDRU

Yan Lou

Timothy Owens

Jaehyeon Park

David Smith

Michael Soth

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-25

Filing date

2009-02-16

Publication date

2011-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40514045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE519763(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-16 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE519763T1 publication Critical patent/ATE519763T1/de

Links

HFTVJMFWJUFBNO-UHFFFAOYSA-N 5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC=CC2=N1 HFTVJMFWJUFBNO-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT09714560T 2008-02-25 2009-02-16 Pyrrolopyrazin-kinasehemmer ATE519763T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3103508P	2008-02-25	2008-02-25
US14651409P	2009-01-22	2009-01-22
PCT/EP2009/051759 WO2009106444A1 (en)	2008-02-25	2009-02-16	Pyrrolopyrazine kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE519763T1 true ATE519763T1 (de)	2011-08-15

Family

ID=40514045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT09714560T ATE519763T1 (de)	2008-02-25	2009-02-16	Pyrrolopyrazin-kinasehemmer

Country Status (18)

Country	Link
US (1)	US8119636B2 (de)
EP (1)	EP2247593B1 (de)
JP (1)	JP5284377B2 (de)
KR (1)	KR20100114095A (de)
CN (1)	CN101952296B (de)
AR (1)	AR070467A1 (de)
AT (1)	ATE519763T1 (de)
AU (1)	AU2009218609A1 (de)
BR (1)	BRPI0907928A2 (de)
CA (1)	CA2713718A1 (de)
CL (1)	CL2009000405A1 (de)
IL (1)	IL206818A0 (de)
MX (1)	MX2010009023A (de)
PE (1)	PE20091738A1 (de)
RU (1)	RU2010139284A (de)
TW (1)	TW200942543A (de)
WO (1)	WO2009106444A1 (de)
ZA (1)	ZA201004942B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE517107T1 (de) *	2008-02-25	2011-08-15	Hoffmann La Roche	Pyrrolopyrazinkinaseinhibitoren
PT2250172E (pt) *	2008-02-25	2011-11-30	Hoffmann La Roche	Inibidores de pirrolpirazina-cinase
MX2011004953A (es)	2008-11-10	2011-12-14	Vertex Pharma	Compuestos utiles como inhibidores de cinasa atr.
ES2921576T3 (es)	2008-12-19	2022-08-29	Vertex Pharma	Compuestos útiles como inhibidores de la quinasa ATR
US8518945B2 (en) *	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8481541B2 (en)	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
NZ603478A (en)	2010-05-12	2014-09-26	Vertex Pharma	2 -aminopyridine derivatives useful as inhibitors of atr kinase
EP2569313A1 (de)	2010-05-12	2013-03-20	Vertex Pharmaceuticals Incorporated	Als art-kinasehemmer nützliche verbindungen
US9334244B2 (en)	2010-05-12	2016-05-10	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2011143419A1 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	Pyrazines useful as inhibitors of atr kinase
EP2569286B1 (de)	2010-05-12	2014-08-20	Vertex Pharmaceuticals Inc.	Verbindungen als hemmer der atr-kinase
US8969356B2 (en)	2010-05-12	2015-03-03	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
KR20130083387A (ko)	2010-05-20	2013-07-22	에프. 호프만-라 로슈 아게	Syk 및 jak 억제제로서 피롤로피라진 유도체
KR20130083386A (ko) *	2010-05-20	2013-07-22	에프. 호프만-라 로슈 아게	피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
EP2585468A1 (de)	2010-06-23	2013-05-01	Vertex Pharmaceuticals Incorporated	Pyrrolo-pyrazinderivate als atr-kinaseinhibitoren
AU2012240030A1 (en)	2011-04-05	2013-10-24	Vertex Pharmaceuticals Incorporated	Aminopyrazine compounds useful as inhibitors of TRA kinase
AU2012255792A1 (en)	2011-05-17	2013-11-07	Principia Biopharma Inc.	Azaindole derivatives as tyrosine kinase inhibitors
US9309250B2 (en)	2011-06-22	2016-04-12	Vertex Pharmaceuticals Incorporated	Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2012178123A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2723747A1 (de)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Als art-kinasehemmer nützliche verbindungen
EP2763990B1 (de) *	2011-09-01	2017-02-22	F. Hoffmann-La Roche AG	Pyrrolopyrazinkinaseinhibitoren
CA2850564A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US8765751B2 (en)	2011-09-30	2014-07-01	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2013049720A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP3878851A1 (de)	2011-09-30	2021-09-15	Vertex Pharmaceuticals Incorporated	Verfahren zur herstellung von verbindungen welche als hemmer der atr-kinase nützlich sind
RU2018108589A (ru)	2011-09-30	2019-02-25	Вертекс Фармасьютикалз Инкорпорейтед	Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
EP2773645A1 (de)	2011-11-01	2014-09-10	F.Hoffmann-La Roche Ag	Imidazopyridazinverbindungen
US8846917B2 (en)	2011-11-09	2014-09-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2776429A1 (de)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Als atr-kinaseinhibitoren nützliche verbindungen
WO2013071090A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2776420A1 (de)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Pyrazinverbindungen als atr-kinaseinhibitoren
JP2015502925A (ja)	2011-11-09	2015-01-29	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
WO2013104573A1 (en)	2012-01-10	2013-07-18	F. Hoffmann-La Roche Ag	Pyridazine amide compounds and their use as syk inhibitors
PT2833973T (pt)	2012-04-05	2017-12-21	Vertex Pharma	Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
EP2888262B1 (de) *	2012-08-21	2018-12-19	F.Hoffmann-La Roche Ag	Pyrrolo[2,3-b]pyrazine als syk inhibitoren
WO2014055756A1 (en)	2012-10-04	2014-04-10	Vertex Pharmaceuticals Incorporated	Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (de)	2012-10-16	2015-08-26	Vertex Pharmaceuticals Incorporated	Als atr-kinaseinhibitoren nützliche verbindungen
WO2014089379A1 (en)	2012-12-07	2014-06-12	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US9663519B2 (en)	2013-03-15	2017-05-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
KR20160007581A (ko) *	2013-05-14	2016-01-20	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피리딘- 또는 피라진-함유 화합물
WO2015085132A1 (en)	2013-12-06	2015-06-11	Vertex Pharmaceuticals Incorporated	2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
HRP20200186T1 (hr)	2014-06-05	2020-05-29	Vertex Pharmaceuticals Inc.	Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja)	2014-06-17	2021-09-15	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
EP3355926B1 (de)	2015-09-30	2025-12-24	Vertex Pharmaceuticals Inc.	Kombination von dna-schädigenden mitteln und atr-inhibitoren zur verwendung in einem verfahren zur behandlung von krebs
US20170100396A1 (en)	2015-10-07	2017-04-13	F. Hoffmann-La Roche Ag	Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
CN115087655A (zh)	2019-12-20	2022-09-20	辉瑞公司	苯并咪唑衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001047922A2 (en)	1999-12-24	2001-07-05	Aventis Pharma Limited	Azaindoles
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
KR20040111445A (ko)	2002-03-28	2004-12-31	에자이 가부시키가이샤	신경퇴행성 질환 치료용 ｃ─ＪｕｎＮ─말단 키나아제억제제로서의 ７─아자인돌
CN1925855B (zh) *	2003-12-19	2010-06-16	普莱希科公司	开发Ret调节剂的化合物和方法
EP1814883A1 (de) *	2004-11-22	2007-08-08	Vertex Pharmaceuticals Incorporated	Bicyclische rho-kinase-hemmer
US7456289B2 (en) *	2004-12-31	2008-11-25	National Health Research Institutes	Anti-tumor compounds
CL2007002617A1 (es)	2006-09-11	2008-05-16	Sanofi Aventis	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
WO2008063888A2 (en) *	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es)	2006-12-21	2008-11-12	Plexxikon Inc	COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
MX2010008198A (es) *	2008-02-25	2010-08-23	Hoffmann La Roche	Inhibidores de cinasa de pirrolopirazina.
PT2250172E (pt) *	2008-02-25	2011-11-30	Hoffmann La Roche	Inibidores de pirrolpirazina-cinase

2009
- 2009-02-16 CA CA2713718A patent/CA2713718A1/en not_active Abandoned
- 2009-02-16 CN CN2009801062407A patent/CN101952296B/zh not_active Expired - Fee Related
- 2009-02-16 AU AU2009218609A patent/AU2009218609A1/en not_active Abandoned
- 2009-02-16 KR KR1020107018679A patent/KR20100114095A/ko not_active Ceased
- 2009-02-16 JP JP2010548070A patent/JP5284377B2/ja not_active Expired - Fee Related
- 2009-02-16 MX MX2010009023A patent/MX2010009023A/es not_active Application Discontinuation
- 2009-02-16 EP EP09714560A patent/EP2247593B1/de not_active Not-in-force
- 2009-02-16 BR BRPI0907928-9A patent/BRPI0907928A2/pt not_active IP Right Cessation
- 2009-02-16 WO PCT/EP2009/051759 patent/WO2009106444A1/en not_active Ceased
- 2009-02-16 RU RU2010139284/04A patent/RU2010139284A/ru unknown
- 2009-02-16 AT AT09714560T patent/ATE519763T1/de not_active IP Right Cessation
- 2009-02-20 US US12/378,837 patent/US8119636B2/en not_active Expired - Fee Related
- 2009-02-23 TW TW098105680A patent/TW200942543A/zh unknown
- 2009-02-23 CL CL2009000405A patent/CL2009000405A1/es unknown
- 2009-02-23 PE PE2009000261A patent/PE20091738A1/es not_active Application Discontinuation
- 2009-02-23 AR ARP090100620A patent/AR070467A1/es unknown
2010
- 2010-07-05 IL IL206818A patent/IL206818A0/en unknown
- 2010-07-13 ZA ZA2010/04942A patent/ZA201004942B/en unknown

Also Published As

Publication number	Publication date
EP2247593A1 (de)	2010-11-10
KR20100114095A (ko)	2010-10-22
IL206818A0 (en)	2010-12-30
RU2010139284A (ru)	2012-04-10
WO2009106444A1 (en)	2009-09-03
CL2009000405A1 (es)	2010-02-26
US20090215785A1 (en)	2009-08-27
AR070467A1 (es)	2010-04-07
CN101952296A (zh)	2011-01-19
JP2011513263A (ja)	2011-04-28
CA2713718A1 (en)	2009-09-03
US8119636B2 (en)	2012-02-21
BRPI0907928A2 (pt)	2015-07-28
JP5284377B2 (ja)	2013-09-11
EP2247593B1 (de)	2011-08-10
CN101952296B (zh)	2013-08-21
PE20091738A1 (es)	2009-11-13
ZA201004942B (en)	2011-12-28
MX2010009023A (es)	2010-09-07
AU2009218609A1 (en)	2009-09-03
TW200942543A (en)	2009-10-16

Legal Events

Date	Code	Title	Description
2012-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DK2247592T3 (da)	2011-09-26	Pyrrolopyrazinkinaseinhibitors
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
CY2020023I2 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
CY2019009I1 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
HUS1900029I1 (hu)	2020-04-28	Kináz inhibitor foszforszármazékok
IL257017A (en)	2018-03-29	Inhibitors of brutons tyrosine kinase
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
BRPI0910668A2 (pt)	2019-09-24	inibidores de proteína quinases
BRPI0922937A2 (pt)	2019-09-24	inibidores de pirrolopirazinil uréia quinase
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
EP2498607A4 (de)	2013-06-19	Kinase-inhibitoren
EP2493313A4 (de)	2013-05-15	Kinase-inhibitoren
BRPI0922962A2 (pt)	2019-09-24	inibidores de p38 map quinase
DK2350047T3 (da)	2013-09-30	p38-MAP-KINASEINHIBITORER
EP2558099A4 (de)	2013-07-17	Kinase-inhibitoren
BRPI0918564A2 (pt)	2015-12-01	inibidores
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
BRPI0912475A2 (pt)	2018-01-09	compostos como inibidores de quinase
BRPI0914936A2 (pt)	2015-10-20	naftiridininonas como inibidores de aurora quinase
BRPI0716198A2 (pt)	2013-11-12	Pirrolo-isoquinolinas como inibidores de cinase
DK2170891T3 (da)	2011-12-12	Pyrazolopyrimidinon-kinasehæmmere
BRPI0912564A2 (pt)	2019-09-24	inibidores de jnk